We are analyzing https://link.springer.com/article/10.1007/s12016-014-8418-y.

Title:
Genetics of Immune-Mediated Adverse Drug Reactions: a Comprehensive and Clinical Review | Clinical Reviews in Allergy & Immunology
Description:
Adverse drug reactions (ADRs) are common and are a major problem in drug therapy. Patients experience unnecessary morbidity and mortality whilst many effective drugs are withdrawn because of ADRs in a minority of patients. Recent studies have demonstrated significant associations between human leukocyte antigens (HLA) and predisposition to ADRs such as drug-induced skin injury (DISI) and drug-induced liver injury (DILI). HLA-B*58:01 has been significantly associated with allopurinol-induced hypersensitivity. Associations between HLA and carbamazepine hypersensitivity reactions demonstrate both ethnicity and phenotype specificity; with HLA-B*15:02 associated with Stevens-Johnson syndrome and toxic epidermal necrolysis in South East Asian patients only whilst HLA-A*31:01 is associated with all phenotypes of hypersensitivity in multiple ethnicities. Studies of ximelagatran, an oral direct thrombin inhibitor withdrawn because of hepatotoxicity, found associations between HLA-DRB1*07:01 and HLA-DQA1*02:01 and ximelagatran DILI. Interestingly, HLA-B*57:01 is associated with both abacavir DISI and flucloxacillin DILI but the reasons for the different phenotype of ADR remains unknown. Pharmacogenetic screening for HLA-B*57:01 prior to abacavir therapy has significantly reduced the incidence of abacavir hypersensitivity syndrome in clinical practice. No other HLA associations have been translated into clinical practice because of multiple reasons including failure to replicate, inadequate sample sizes, and our lack of understanding of pathophysiology of ADRs. Here, we review genetic associations that have been reported with ADRs and discuss the challenges that scientists, clinicians, pharmaceutical industry and regulatory agencies face when attempting to translate these associations into clinically valid and cost-effective tests to reduce the burden of ADRs in future.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,643,078 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure if the website is profiting.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

pubmed, google, scholar, cas, reactions, drug, hypersensitivity, adverse, hlab, patients, liver, hla, abacavir, central, druginduced, clinical, pirmohamed, injury, cutaneous, clin, pharmacogenomics, syndrome, genetic, association, study, carbamazepineinduced, allele, stevensjohnson, pharmacol, ther, article, alfirevic, screening, med, aids, associations, risk, review, carbamazepine, prospective, severe, analysis, research, allergy, human, toxic, hiv, reaction, adrs, drugs,

Topics {✒️}

gov/downloads/aboutfda/centersoffices/cder/whatwedo/ucm078935 gov/downloads/drugs/scienceresearch/researchareas/ucm122149 allopurinol-induced stevens-johnson syndrome allopurinol-related stevens–johnson syndrome carbamazepine-induced stevens-johnson syndrome drug-induced skin injury angiotensin-converting enzyme-inhibitor perindopril human leukocyte antigen amoxicillin-clavulanate-induced liver injury drug-induced liver injury cd4 + cd8+ t-cell clones drug-induced hypersensitivity reactions amoxiclav-induced liver injury carbamazepine-induced hypersensitivity reactions lumiracoxib-related liver injury genome-wide pharmacogenetic investigation stevens-johnson syndrome stevens–johnson syndrome drug-induced hepatic injuries human leukocyte antigens month download article/chapter allopurinol-induced hypersensitivity carbamazepine-induced toxic effects adverse drug reactions allopurinol-induced scars antigen-specific cd4+ nevirapine-induced dermatological reaction glucose-6-phosphate dehydrogenase deficiency amoxicillin-clavulanate-induced hepatitis preliminary case–control study abacavir hypersensitivity syndrome french population-based study acute liver injury cutaneous hypersensitivity induced hcp5 single-nucleotide polymorphism medical research council drug-induced hepatotoxicity hla-genotyped dna archive hla-dependent hypersensitivity reaction antiretroviral-treated hiv-1 patients hiv-infected thai patients flucloxacillin prescribing habits abacavir hypersensitivity reactions systemic drug hypersensitivity ticlopidine-induced hepatotoxicity bullous cutaneous reactions hepatic adverse event hepatic adverse events drug safety acute liver failure

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Genetics of Immune-Mediated Adverse Drug Reactions: a Comprehensive and Clinical Review
         description:Adverse drug reactions (ADRs) are common and are a major problem in drug therapy. Patients experience unnecessary morbidity and mortality whilst many effective drugs are withdrawn because of ADRs in a minority of patients. Recent studies have demonstrated significant associations between human leukocyte antigens (HLA) and predisposition to ADRs such as drug-induced skin injury (DISI) and drug-induced liver injury (DILI). HLA-B*58:01 has been significantly associated with allopurinol-induced hypersensitivity. Associations between HLA and carbamazepine hypersensitivity reactions demonstrate both ethnicity and phenotype specificity; with HLA-B*15:02 associated with Stevens-Johnson syndrome and toxic epidermal necrolysis in South East Asian patients only whilst HLA-A*31:01 is associated with all phenotypes of hypersensitivity in multiple ethnicities. Studies of ximelagatran, an oral direct thrombin inhibitor withdrawn because of hepatotoxicity, found associations between HLA-DRB1*07:01 and HLA-DQA1*02:01 and ximelagatran DILI. Interestingly, HLA-B*57:01 is associated with both abacavir DISI and flucloxacillin DILI but the reasons for the different phenotype of ADR remains unknown. Pharmacogenetic screening for HLA-B*57:01 prior to abacavir therapy has significantly reduced the incidence of abacavir hypersensitivity syndrome in clinical practice. No other HLA associations have been translated into clinical practice because of multiple reasons including failure to replicate, inadequate sample sizes, and our lack of understanding of pathophysiology of ADRs. Here, we review genetic associations that have been reported with ADRs and discuss the challenges that scientists, clinicians, pharmaceutical industry and regulatory agencies face when attempting to translate these associations into clinically valid and cost-effective tests to reduce the burden of ADRs in future.
         datePublished:2014-04-30T00:00:00Z
         dateModified:2014-04-30T00:00:00Z
         pageStart:165
         pageEnd:175
         sameAs:https://doi.org/10.1007/s12016-014-8418-y
         keywords:
            Adverse drug reactions
            Drug-induced skin injury
            Drug-induced liver injury
            Human leukocyte antigen
            Maculopapular exanthema
            Hypersensitivity syndrome
            Stevens-Johnson syndrome
            Hypersensitivity
            Abacavir
            Allopurinol
            Carbamazepine
            Flucloxacillin
            Ximelagatran
            Allergology
            Immunology
            Internal Medicine
         image:
         isPartOf:
            name:Clinical Reviews in Allergy & Immunology
            issn:
               1559-0267
               1080-0549
            volumeNumber:48
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:V. L. M. Yip
               affiliation:
                     name:The University of Liverpool, The Wolfson Centre for Personalised Medicines
                     address:
                        name:Department of Molecular and Clinical Pharmacology, The University of Liverpool, The Wolfson Centre for Personalised Medicines, Liverpool, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:A. Alfirevic
               affiliation:
                     name:The University of Liverpool, The Wolfson Centre for Personalised Medicines
                     address:
                        name:Department of Molecular and Clinical Pharmacology, The University of Liverpool, The Wolfson Centre for Personalised Medicines, Liverpool, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M. Pirmohamed
               affiliation:
                     name:The University of Liverpool, The Wolfson Centre for Personalised Medicines
                     address:
                        name:Department of Molecular and Clinical Pharmacology, The University of Liverpool, The Wolfson Centre for Personalised Medicines, Liverpool, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Genetics of Immune-Mediated Adverse Drug Reactions: a Comprehensive and Clinical Review
      description:Adverse drug reactions (ADRs) are common and are a major problem in drug therapy. Patients experience unnecessary morbidity and mortality whilst many effective drugs are withdrawn because of ADRs in a minority of patients. Recent studies have demonstrated significant associations between human leukocyte antigens (HLA) and predisposition to ADRs such as drug-induced skin injury (DISI) and drug-induced liver injury (DILI). HLA-B*58:01 has been significantly associated with allopurinol-induced hypersensitivity. Associations between HLA and carbamazepine hypersensitivity reactions demonstrate both ethnicity and phenotype specificity; with HLA-B*15:02 associated with Stevens-Johnson syndrome and toxic epidermal necrolysis in South East Asian patients only whilst HLA-A*31:01 is associated with all phenotypes of hypersensitivity in multiple ethnicities. Studies of ximelagatran, an oral direct thrombin inhibitor withdrawn because of hepatotoxicity, found associations between HLA-DRB1*07:01 and HLA-DQA1*02:01 and ximelagatran DILI. Interestingly, HLA-B*57:01 is associated with both abacavir DISI and flucloxacillin DILI but the reasons for the different phenotype of ADR remains unknown. Pharmacogenetic screening for HLA-B*57:01 prior to abacavir therapy has significantly reduced the incidence of abacavir hypersensitivity syndrome in clinical practice. No other HLA associations have been translated into clinical practice because of multiple reasons including failure to replicate, inadequate sample sizes, and our lack of understanding of pathophysiology of ADRs. Here, we review genetic associations that have been reported with ADRs and discuss the challenges that scientists, clinicians, pharmaceutical industry and regulatory agencies face when attempting to translate these associations into clinically valid and cost-effective tests to reduce the burden of ADRs in future.
      datePublished:2014-04-30T00:00:00Z
      dateModified:2014-04-30T00:00:00Z
      pageStart:165
      pageEnd:175
      sameAs:https://doi.org/10.1007/s12016-014-8418-y
      keywords:
         Adverse drug reactions
         Drug-induced skin injury
         Drug-induced liver injury
         Human leukocyte antigen
         Maculopapular exanthema
         Hypersensitivity syndrome
         Stevens-Johnson syndrome
         Hypersensitivity
         Abacavir
         Allopurinol
         Carbamazepine
         Flucloxacillin
         Ximelagatran
         Allergology
         Immunology
         Internal Medicine
      image:
      isPartOf:
         name:Clinical Reviews in Allergy & Immunology
         issn:
            1559-0267
            1080-0549
         volumeNumber:48
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:V. L. M. Yip
            affiliation:
                  name:The University of Liverpool, The Wolfson Centre for Personalised Medicines
                  address:
                     name:Department of Molecular and Clinical Pharmacology, The University of Liverpool, The Wolfson Centre for Personalised Medicines, Liverpool, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:A. Alfirevic
            affiliation:
                  name:The University of Liverpool, The Wolfson Centre for Personalised Medicines
                  address:
                     name:Department of Molecular and Clinical Pharmacology, The University of Liverpool, The Wolfson Centre for Personalised Medicines, Liverpool, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M. Pirmohamed
            affiliation:
                  name:The University of Liverpool, The Wolfson Centre for Personalised Medicines
                  address:
                     name:Department of Molecular and Clinical Pharmacology, The University of Liverpool, The Wolfson Centre for Personalised Medicines, Liverpool, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Clinical Reviews in Allergy & Immunology
      issn:
         1559-0267
         1080-0549
      volumeNumber:48
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:The University of Liverpool, The Wolfson Centre for Personalised Medicines
      address:
         name:Department of Molecular and Clinical Pharmacology, The University of Liverpool, The Wolfson Centre for Personalised Medicines, Liverpool, UK
         type:PostalAddress
      name:The University of Liverpool, The Wolfson Centre for Personalised Medicines
      address:
         name:Department of Molecular and Clinical Pharmacology, The University of Liverpool, The Wolfson Centre for Personalised Medicines, Liverpool, UK
         type:PostalAddress
      name:The University of Liverpool, The Wolfson Centre for Personalised Medicines
      address:
         name:Department of Molecular and Clinical Pharmacology, The University of Liverpool, The Wolfson Centre for Personalised Medicines, Liverpool, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:V. L. M. Yip
      affiliation:
            name:The University of Liverpool, The Wolfson Centre for Personalised Medicines
            address:
               name:Department of Molecular and Clinical Pharmacology, The University of Liverpool, The Wolfson Centre for Personalised Medicines, Liverpool, UK
               type:PostalAddress
            type:Organization
      name:A. Alfirevic
      affiliation:
            name:The University of Liverpool, The Wolfson Centre for Personalised Medicines
            address:
               name:Department of Molecular and Clinical Pharmacology, The University of Liverpool, The Wolfson Centre for Personalised Medicines, Liverpool, UK
               type:PostalAddress
            type:Organization
      name:M. Pirmohamed
      affiliation:
            name:The University of Liverpool, The Wolfson Centre for Personalised Medicines
            address:
               name:Department of Molecular and Clinical Pharmacology, The University of Liverpool, The Wolfson Centre for Personalised Medicines, Liverpool, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Molecular and Clinical Pharmacology, The University of Liverpool, The Wolfson Centre for Personalised Medicines, Liverpool, UK
      name:Department of Molecular and Clinical Pharmacology, The University of Liverpool, The Wolfson Centre for Personalised Medicines, Liverpool, UK
      name:Department of Molecular and Clinical Pharmacology, The University of Liverpool, The Wolfson Centre for Personalised Medicines, Liverpool, UK
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(260)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.66s.

LINK . SPRINGER . COM {}